Clinical Trial Search

Primary: Participants Experiencing Device- or Procedure-Related Serious Adverse Events (SAE) — 0 Number of Participants with related SAE

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 4; 4; 2; 2 Participants

Primary: Stage 1: Number of Participants With Adverse Events (AEs) — 14 Participants

Primary: Brief Pain Inventory (BPI)- Short Form (SF) Question 3 (BPI-SF3) - Mean Change From Baseline — 7.1; 7.4; 8.1; -2.8 units on a scale

Primary: Change From Baseline to Week 52 in Opacification of Sinuses Assessed by CT Scan Using the LMK Score — -1.81; -9.17 score on a scale — p=<0.0001

Primary: Analysis of the National Institutes of Health Stroke Scale (NIHSS) Total Score Area Under the Curve During the Treatment Period — 3.83; 3.13 units on a scale

Primary: Percentage of Participants Assessed as At Least 1-point Improvement From Baseline on Medicis Lip Fullness Scale (MLFS) — 94.7; 94.7 percentage of participants

Primary: Percentage of Eligible Participants Who Agreed to Participate as Assessed by Tracking Those Who Were Approached to Participate and Those Who Agreed to Participate — 14…

Primary: Disease Control Rate (DCR) at 18 Weeks — 20; 17 percentage of participants

Primary: Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug — -3.7; -3.8 days/month — p=0.8484

Primary: Change in Weight in Pounds From Week 0 to Week 24 — -27.41 pounds

Primary: Number of Participants Who Experienced Graft Failure — 0 Participants

Primary: Harris Hip Score — 45.8; 43.1; 50.7; 95.4 Score

Primary: Change Score in Liking/Wanting of E-cigarette — -1.06; -5.59; -7.14; -7.63 units on scale

Primary: Intracellular Level of Tenofovir Diphosphate Levels Via Dried Blood Spot at 6-month Follow-up — NA fmol/punch